Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientif...( MOUNTAIN VIEW Calif. Oct. 29 /- VIVUS...),Health

MOUNTAIN VIEW, Calif., Oct. 29 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that additional data on Qnexa(TM), an investigational drug candidate for obesity, was presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley W. Day, PhD, vice president of clinical development at VIVUS, presented the additional data from the company's two year-long phase 3 obesity trials during the Pharmacotherapy Update portion of the pre-conference on October 24, 2009. Top-line results from the phase 3 studies were previously reported in September 2009. The presentation included data from the EQUIP (OB-302) and CONQUER (OB-303) studies that further supports the safety and efficacy profile of Qnexa.

The additional efficacy data from the EQUIP study that was presented included weight loss by BMI category, on an intent-to-treat, last observation carried forward (ITT-LOCF) basis for full dose Qnexa.

                     Percent Weight Loss (ITT-LOCF)
                     ------------------------------

    Baseline BMI                Placebo             Full Dose Qnexa
    ------------                -------             ---------------
    >35-40                        1.8%                    10.7%
    >40-45                        1.3%                    11.1%
    >45-50                        1.0%                    11.8%
    >50                           2.0%                    10.3%

"The EQUIP study was designed to look at the effect of Qnexa on morbidly obese patients, that is, those patients with a baseline BMI of 35 or greater. The average baseline BMI in the EQUIP study was 42.1. A review of results by baseline BMI show a consistent effect across a broad range of patients based on starting body weight," stated Wesley W. Day. "On an ITT-LOCF basis,
'/>"/>